Chemotherapy in elderly patients with metastatic gastric cancer; a single Turkish cancer center experience

Aim To analyze the results of chemotherapy applied at the Bülent Ecevit University School of Medicine, Department of Medical Oncology, to elderly patients with metastatic gastric cancer (GC). Methods The study retrospectively investigated hospital records including pathological reports, imaging records, chemotherapy regimens, response and toxicity profile. All patients received systemic chemotherapy for pathologically proven metastatic GC at the Bülent Ecevit University School of Medicine, Department of Medical Oncology. Results From 2005 to 2012, 23 metastatic GC patients older than 70 years were treated with systemic chemotherapy as a first-line therapy. As the first-line chemotherapy, 17 (74%) patients received polychemotherapy and the remaining six (26%) patients received monotherapy. Overall, 113 cycles were administered. The median progression free survival (PFS) for the first-line chemotherapy was 6 months (95% CI, 0-16) and the median overall survival (OS) was 14 months (95% CI, 3-30). Multivariate analysis revealed that decreased OS was significantly associated with poor Eastern Cooperative Oncology Group (ECOG) performance status (p=0.045), elevated carcinoembryonic antigen (CEA) levels at the diagnosis time (p = 0.040) and decreased number of chemotherapy cycles (p=0.019) with R-Sq (adj) = 41, 6%. One patient had a complete response with docetaxel, cisplatin and fluorouracil combined (DCF) regimen and had 12 months of disease free survival (DFS). Conclusion This is the first study investigating the outcomes of chemotherapy in Turkish elderly metastatic GC patients. Docetaxel, cisplatin and fluorouracil combination were the most common regimen, which is a tolerable and effective choice in elderly patients who had good performance status.

Dergi Adı Medicinski Glasnik
Dergi Cilt Bilgisi 10
Dergi Sayısı 2
Sayfalar 298 - 303
Yayın Yılı 2013
Eser Adı
[dc.title]
Chemotherapy in elderly patients with metastatic gastric cancer; a single Turkish cancer center experience
Yazar
[dc.contributor.author]
Bilir C.
Yazar
[dc.contributor.author]
Engin H.
Yazar
[dc.contributor.author]
Bakkal, Bekir Hakan
Yazar
[dc.contributor.author]
Ilikhan S.U.
Yazar
[dc.contributor.author]
Malkoç D.
Yayın Yılı
[dc.date.issued]
2013
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Aim To analyze the results of chemotherapy applied at the Bülent Ecevit University School of Medicine, Department of Medical Oncology, to elderly patients with metastatic gastric cancer (GC). Methods The study retrospectively investigated hospital records including pathological reports, imaging records, chemotherapy regimens, response and toxicity profile. All patients received systemic chemotherapy for pathologically proven metastatic GC at the Bülent Ecevit University School of Medicine, Department of Medical Oncology. Results From 2005 to 2012, 23 metastatic GC patients older than 70 years were treated with systemic chemotherapy as a first-line therapy. As the first-line chemotherapy, 17 (74%) patients received polychemotherapy and the remaining six (26%) patients received monotherapy. Overall, 113 cycles were administered. The median progression free survival (PFS) for the first-line chemotherapy was 6 months (95% CI, 0-16) and the median overall survival (OS) was 14 months (95% CI, 3-30). Multivariate analysis revealed that decreased OS was significantly associated with poor Eastern Cooperative Oncology Group (ECOG) performance status (p=0.045), elevated carcinoembryonic antigen (CEA) levels at the diagnosis time (p = 0.040) and decreased number of chemotherapy cycles (p=0.019) with R-Sq (adj) = 41, 6%. One patient had a complete response with docetaxel, cisplatin and fluorouracil combined (DCF) regimen and had 12 months of disease free survival (DFS). Conclusion This is the first study investigating the outcomes of chemotherapy in Turkish elderly metastatic GC patients. Docetaxel, cisplatin and fluorouracil combination were the most common regimen, which is a tolerable and effective choice in elderly patients who had good performance status.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Cancer
Konu Başlıkları
[dc.subject]
Chemotherapy
Konu Başlıkları
[dc.subject]
Older adults
Konu Başlıkları
[dc.subject]
Stomach
Haklar
[dc.rights]
info:eu-repo/semantics/openAccess
ISSN
[dc.identifier.issn]
1840-0132
İlk Sayfa Sayısı
[dc.identifier.startpage]
298
Son Sayfa Sayısı
[dc.identifier.endpage]
303
Dergi Adı
[dc.relation.journal]
Medicinski Glasnik
Dergi Sayısı
[dc.identifier.issue]
2
Dergi Cilt Bilgisi
[dc.identifier.volume]
10
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/4654
Tek Biçim Adres
[dc.identifier.uri]
https://pubmed.ncbi.nlm.nih.gov/23892848/
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
22
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
15 Nisan 2024 04:38
Google Kontrol
Tıklayınız
chemotherapy patients metastatic Oncology received first-line elderly months survival median fluorouracil decreased systemic regimen status cisplatin performance response cycles University Medicine School Ecevit Department Bülent Medical records diagnosis antigen levels carcinoembryonic elevated choice (ECOG) Cooperative
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms